Clinical Trials

154 enrolled 18 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT02518555 2026-04-06

Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

42 enrolled

Phase 1 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02537613 2026-04-01

A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

54 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02629809 2026-03-06

Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia

81 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03514017 2026-03-02

Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia

5 enrolled 11 charts

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02756897 2026-02-19

Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia

234 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02649387 2026-02-10

MERIT

35 enrolled 7 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03513562 2026-02-06

Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations

28 enrolled

Phase 1/2 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02427451 2026-01-27

Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia

87 enrolled 30 charts

Phase 1 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03447808 2026-01-07

Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

15 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03708003 2025-12-30

Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL

30 enrolled

Leukemia, Leukemia, Lymphoid, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04230304 2025-12-30

Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study

8 enrolled 10 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07052695 2025-12-15

Mosunetuzumab for CLL MRD Clearance

Phase 1/2 Recruiting

40 enrolled

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02666898 2025-11-26

ICLL07GAI

135 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm, Residual

NCT03734198 2025-11-26

IDA53

29 enrolled

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06958705 2025-11-25

Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy

79 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03128879 2025-11-21

Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

90 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02827617 2025-11-18

Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia

Completed

56 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02251548 2025-10-24

iFCR

85 enrolled 17 charts

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02315768 2025-09-15

Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.

Phase 1/2 Completed

32 enrolled 9 charts

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03207555 2025-09-02

Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)

23 enrolled 9 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02303392 2025-06-10

Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

34 enrolled 14 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT04685915 2025-05-22

Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL

Phase 2 Withdrawn

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04781855 2025-02-28

Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation

Phase 1 Withdrawn

Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms

NCT02388048 2025-01-29

Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia

19 enrolled

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02863718 2024-12-30

CLL12

Phase 3 Completed

515 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02950051 2024-12-30

GAIA

Phase 3 Completed

926 enrolled

Phase 1/2 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03153202 2024-11-19

Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)

23 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT02268851 2024-11-15

A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL

45 enrolled 13 charts

Phase 1 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT03422393 2024-07-05

Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib

24 enrolled

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Disease Progression

NCT02420912 2024-03-20

Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation

37 enrolled 12 charts

Chromosome 17 deletion, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02332980 2024-01-03

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

65 enrolled 21 charts

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT04439006 2023-12-26

Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

Classical hematologyMyeloidOther hematologic neoplasm

10 enrolled

Anemia, Aplastic, Monoclonal Gammopathy of Undetermined Significance, Myelodysplastic Syndromes, Hematologic Neoplasms

NCT05694312 2023-12-01

Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL

Classical hematologyLymphoidOther hematologic neoplasm

45 enrolled

Anemia, Hemolytic, Autoimmune, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02869633 2023-10-23

Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant

23 enrolled 10 charts

Hodgkin Disease, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT04758975 2023-10-04

VALUABLE

55 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04908228 2023-10-03

FIGHT

53 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03267186 2023-08-01

Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant

LymphoidMyeloidOther hematologic neoplasm

8 enrolled 13 charts

Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03145480 2023-06-01

Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients

Other hematologic neoplasm

3 enrolled 5 charts

Leukemia

NCT03121534 2023-02-17

Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation

Other hematologic neoplasm

9 enrolled 10 charts

Hematologic Neoplasms

NCT02758665 2023-01-17

CLL2-GiVe

41 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03454165 2023-01-04

A Study of BNC105P Combined With Ibrutinib

6 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02553941 2022-10-06

Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome

Other hematologic neoplasm

21 enrolled

Leukemia, Myelomonocytic, Chronic

NCT03280160 2022-09-16

Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab

Phase 2 Unknown

84 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04665115 2022-08-03

Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)

Phase 2 Withdrawn

Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03943342 2021-11-05

Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance

Phase 2 Withdrawn